Novartis’ Entresto, Medicare Price Negotiation And The Impact Of ‘Bona Fide’ Competition

Entresto may be subject to a negotiated price in Medicare Part D for one year before it will be excused because of generic competition under the government's current approach to implementing the program, Novartis predicted. The program could also envelop Kisqali in a few years, but the firm is not making adjustments on Leqvio and pelacarsen in response to the IRA.